Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Transmyocardial Laser Revascularization

  • Author: Shabir Bhimji, MD, PhD; Chief Editor: Brett C Sheridan, MD, FACS  more...
 
Updated: Jul 31, 2015
 

Overview

Background

Despite advances in both medical and surgical management of coronary artery disease (CAD), many patients remain symptomatic after conventional therapies have been exhausted. Typically, these patients continue to have chest pain while on maximal medical therapy, and most are at an extraordinary risk for surgical intervention.

Transmyocardial laser revascularization (TMLR) is based on the use of a high-powered carbon dioxide or other laser that interjects a strong energy pulse into the left ventricle, vaporizing the ventricular muscle and creating a transmural channel with a 1-mm diameter. The precise physiologic mechanism for its efficacy is not thoroughly understood.

Although coronary artery bypass grafting (CABG) is effective in many patients, some are not candidates for direct revascularization procedures. In the past few years, TMLR has elicited significant interest in the treatment of otherwise surgically untreatable CAD. The results of several large clinical studies show marked improvements in angina. These improvements appear instantaneously after TMLR and are sustained. In most cases, a comparable improvement in exercise tolerance occurs. Regional myocardial perfusion also may be improved, but this has not been convincingly confirmed on thallium scintigraphy.

The marked improvement in patients with chronic angina has led the US Food and Drug Administration (FDA) to approve TMLR for such use. In addition to the carbon dioxide laser energy source, alternative devices using the yttrium-aluminum-garnet (YAG) and excimer lasers have been studied.[1] The latter two sources use fiberoptic technology and are being evaluated for percutaneous approaches.

The first attempts at improving myocardial blood supply were designed to increase collateral circulation from extracardiac sources. In 1935, Beck used a burr to drill holes into the epicardium and pericardium, intending to stimulate ingrowth of new vessels into the ischemic myocardium.

In 1941, Schlesinger and Zoll observed that intramyocardial arterioles were not prone to arteriosclerosis. This prompted Vineberg to implant the left internal mammary artery (LIMA) directly onto the myocardium with the purpose of developing collaterals between the LIMA and the intramyocardial arterioles. Although the first patient to undergo the Vineberg procedure died 2 days later, the LIMA was demonstrated to be widely patent at autopsy. Vineberg later created an intramyocardial tunnel prior to LIMA implantation, and patency of these grafts was documented two decades later.

In 1965, Sen et al studied the benefits of transmyocardial channels produced with needle punctures.[2] Using a canine model, they placed numerous needle punctures in an ischemic area subtended by an occluded left anterior descending artery. They showed that the acupuncture-created channels resulted in decreased mortality, increased long-term survival, and decreased infarct size. Although patent channels were identified at 8 weeks, no evidence suggested that the channels had developed an endothelial cell lining, thus confirming successful rearterialization.

In 1968, Sen et al described marked improvements in patients with chronic angina following transmyocardial revascularization.[3] These initial data supported attempts to improve myocardial perfusion by creating mechanisms for a direct flow of blood from the ventricular cavity to the myocardium, thus mimicking the anatomy of the reptilian heart, in which much of the myocardium is perfused with blood directly from the ventricular cavity.

During the next two decades, numerous studies were undertaken to evaluate the effects of needle-created transmyocardial channels in revascularizing ischemic myocardium. However, much of this research received little attention because it was not considered nearly as promising as the emerging techniques involving direct myocardial revascularization, such as CABG and angioplasty.

The development of laser energy sources in the 1980s stimulated investigators to restudy myocardial acupuncture. In 1981, Mirhoseini and Cayton demonstrated that the carbon dioxide laser could generate small transmyocardial channels in the ischemic myocardium of a dog.[4] In 1983, Mirhoseini et al used TMLR on a patient with CAD.[5] They used a carbon dioxide laser in conjunction with CABG to treat a hypokinetic area of the left ventricle. The patient did well, with normal ventricular function demonstrated during a postoperative nuclear scan.

These initial clinical studies provided further impetus for the use of TMLR. Since the early 1990s, carbon dioxide laser systems have been used to perform TMLR in humans, with excellent results. A holmium:YAG system has also been approved by the FDA.[6]

For patient education resources, see the Heart Health Center, as well as Angina Pectoris and Coronary Heart Disease.

Indications

Although no absolute indications have been described for the application of TMLR, several studies have provided some necessary guidelines.

Most patients have diffuse disease, either locally or globally, such that no target vessel is available for either percutaneous transluminal coronary angioplasty (PTCA) or bypass grafting. Furthermore, the appropriate patient is symptomatic from disease in an area of the myocardium that is not treatable by conventional techniques and has not responded to maximal medical therapy.

Before TMLR is undertaken, a nuclear perfusion scan is obtained, the results of which must show evidence of reversible ischemia. Patients with infarcted or scarred tissue are not suitable candidates for TMLR. Patients should have reasonable ventricular function, with left ventricular ejection fractions above 20%.

Historically, patients enrolled in TMLR clinical trials had severe CAD with Canadian Heart Association class III or IV angina despite maximal medical therapy. The patients had a left ventricular ejection fraction above 20% and were on maximal antianginal therapy.

Contraindications

The reported mortality (7-10%) following TMLR is a significant cause for caution. Risk-factor assessment has shown that patients with unstable angina and poor myocardial function are at relatively greater risk. If patients have an ejection fraction greater than 30% and chronic stable angina, their risk may be minimized. In addition, patients must have a viable region of the myocardium for TMLR. Patients with scarred or infarcted tissue are not appropriate candidates. Patients with severe adhesions from prior coronary artery bypass surgery can have significant bleeding if a median sternotomy approach is used; therefore, in these patients, a left anterior thoracotomy may be an alternative.

Technical considerations

Initially, researchers believed that two components were necessary to the success of TMLR for revascularizing myocardium. The first component was thought to be a physical effect: TMLR channels were thought to remain patent secondary to the high intraluminal pressure within the left ventricle. These patent channels would become small sinuses from which diffusion could occur deep within the once-ischemic myocardium and from which cardiac capillaries could communicate and draw oxygen.

This subject has been an area of debate, and histologic data are controversial. Some researchers have observed patency in these channels for a 2-week period, followed by complete occlusion in humans. In animal models, postoperative patency has been achieved for more than 12 months. Studies by Gassler et al, describing the histologic features of TMLR at autopsy at various time intervals,[7] showed that no patent channels were created and that endothelialization did not occur. Thus, the investigators concluded that the histologic steps following TMLR are much like those of wound healing following necrosis, resulting in a fibrous scar. They did not describe the clinical response to TLMR in these patients prior to death.

Stimulated by the ongoing debate over the long-term patency of laser channels, several centers have reported results of histologic analyses of tissues from patients who died after TMLR. To date, no researchers have reported patent channels from clinical material. Early development of a capillary network has been observed, but the results have not been consistent. Some believe that angiogenesis resulting from the inflammatory response, as opposed to the patent channel hypothesis, may be the reason for improved perfusion.

The second component of successful TMLR is based on the hypothesis that the laser channels activate wound repair mechanisms, thus resulting in increased angiogenesis. This hypothesis is supported by Gassler et al, who noted extensive capillary networks around the laser-created channels in histology sections from a patient 150 days after surgery. The formation of a fibrous scar and the development of capillary networks suggest that the laser actually necroses myocytes, thereby initiating an inflammatory response that, in turn, results in angiogenesis and improved myocardial microperfusion.

A proposed explanation for the success of TMLR is that the process of using a laser to create channels in the ischemic area of the left ventricle actually causes denervation of the myocardium. Sundt and Kwong noticed a significant decrease in patient symptoms after TMLR.[8] Using the holmium:yttrium-aluminum-garnet (YAG) laser, they performed laser revascularization in canine hearts. Microscopic analysis revealed that laser treatment of the heart tissue might damage or even destroy nerve fibers and thus reduce the symptoms of angina. However, if this were the sole reason for the success of TMLR initially, the long-term outcomes would not be positive, because the original problem of ischemic myocardium would continue to worsen.

Denervation may play a role in the success of TMR, depending on the type of laser utilized, but the positive effects of denervation are in addition to the increased blood flow that occurs over time related to the other mechanisms of action that make TMR a successful therapy.

Outcomes

Most clinical studies show that TMLR, regardless of the type of laser used, results in profound and almost immediate improvement in angina pectoris among patients with inoperable CAD. This improvement appears to be sustained throughout the first year. TMLR also offers advantages over CABG in that it does not require arresting the heart or cardiopulmonary bypass (CPB).

A review of TMLR by the FDA recommended that TMLR not be considered experimental, because the latest data support its efficacy and safety. Clinical trials are in progress that randomize patients to continued medical therapy or to TMLR. A 2015 Cochrane review of TMLR versus medical therapy for refractory angina concluded that overall, the risks associated with TMLR outweighed the potential clinical benefits.[9]

Trials are also under way that compare TMLR with reoperative CABG. Other studies are examining the use of TMLR in combination with CABG. If the combination of TMLR and CABG proves beneficial, TMLR could be used in areas where bypass grafting is not possible. TMLR may prove helpful in the treatment of cardiac transplantation patients with diffuse atherosclerosis. Also, TMLR will most likely be performed via minimally invasive approaches in the future.

The use of TMLR via the endocardial approach is an important subject of clinical study. TMLR performed via the endocardial approach creates transmural channels through the myocardium, initiated at the endocardial surface and extended toward the pericardium, by using the holmium:YAG laser. The obvious benefits of this technique are that it can be performed via a percutaneous approach in the cardiac catheterization laboratory and that it obviates the need for surgery.

A robotically assisted completely endoscopic approach to TMLR was found to be feasible and effective in a study of 42 patients with Canadian Cardiovascular Score class IV angina at baseline.[10]

Clinical investigations are evaluating alternative energy sources potentially adaptable to endovascular applications. The final use of this type of treatment, whether delivered percutaneously or surgically, will be determined only when the results of prospectively randomized trials of maximum medical therapy versus TMLR are available and the impact of this therapy on survival and symptom relief are known.

Short-term clinical experience

Numerous studies have reported on the use of TMLR. In most patients, preoperative and postoperative evaluations include positron emission tomography (PET), dobutamine echocardiography, thallium stress testing, radionuclide ventriculography, and an exercise treadmill test to evaluate the results of TMLR. Thallium dipyridamole scans and dobutamine stress echocardiograms have shown an overall definite, statistically significant reduction in the severity and extent of ischemic myocardium and improvements in resting function and contractile reserve.

The initial report by Mirhoseini et al on 12 patients whose conditions were refractory to medical treatment and who were not candidates for either CAGB or angioplasty revealed no deaths, and all patients improved both clinically and according to nuclear scan findings. This initial report and subsequent follow-up eventually led to phase 2 trials. Frazier et al reported the use of TMLR in 21 patients with medically refractory, chronic stable angina who were not candidates for traditional revascularization procedures.[11] This study showed a concomitant reduction in antianginal medications and cardiac-related hospital admissions.

Without question, the most dramatic clinical effect of TMLR has been a significant reduction in angina pectoris. In patients with Canadian Heart Association stage III or IV angina, perioperative mortality was 9%. Postoperatively, most patients improved to class II or better. Remarkably, much of this benefit was observed immediately after the operation. In multicenter studies, one third of patients reported complete relief of angina, whereas two thirds experienced at least a two-class reduction in symptoms. In addition, the admission rate for angina pectoris in multicenter series dropped significantly in patients treated with TMLR. Note that myocardial perfusion, as determined by single-photon emission computed tomography (SPECT), was significantly improved in ischemic areas that had received TMLR.

Long-term studies have unequivocally demonstrated the superiority of TMLR in decreasing angina. Five-year follow-up of patients who had refractory class IV angina and were not candidates for conventional therapy demonstrated significantly increased Kaplan-Meier survival estimates in patients randomized to TMLR. The significant angina relief observed 12 months after sole TMLR therapy was sustained over the long term and continued to be superior to that observed for patients maintained on continual medical management alone.

Improvements in myocardial perfusion after TMLR have been less convincing than its impact on clinical symptoms. Study findings have not been uniform, with most showing no difference between baseline and 12-month studies of ejection fraction using nuclear studies. In addition, studies have not defined major differences in short-term morbidity and mortality between the holmium:YAG laser and the CO 2 laser in the setting of TMLR.[12]

TMLR has also been used in cardiac transplantation patients who have accelerated graft atherosclerosis documented by angiography findings. Angiograms revealing patency of channels after TMLR in symptomatic patients have been described.[13]

Reports indicate that TMLR provides excellent relief of angina in these patients. Clinical trials have been initiated in many centers in the United States and Europe.

TMLR has been combined with intramyocardial autologous endothelial progenitor cell injections for angina relief. To date, studies have only included a small number of patients, and the follow-up has been short. The one conclusion derived from the study is the great caution should be exercised when this therapy is employed in patients with depressed left ventricular function.[14]

CABG combined with TMLR

Over the past few years, increasing evidence has shown that TMLR may be more useful as a hybrid procedure when used in combination with CABG. Several randomized studies have shown that the combination of TMLR and CABG yields more clinical benefit than TMLR or CABG alone. In a prospective, randomized trial involving 263 patients who were not completely revascularized with CABG alone, the addition of TMLR to conventional CABG provided superior anginal relief as compared with CABG alone.

Other studies have shown similar results. When TMLR was used (both alone and in combination with CABG), substantial improvement was noted with regard to the anginal score, exercise tolerance, and left ventricular function 6 months after the procedure. In summary, most studies have shown that TMLR, as an adjunct to CABG in selected patients with limited options, may improve hospital outcomes.

Next

Periprocedural Care

Preprocedural evaluation

Although clinical trials studying the effects of transmyocardial laser revascularization (TMLR) differ in protocol, eligible patients are provided information regarding the potential benefits and risks of this procedure. The workup before the procedure includes a complete history, physical examination, chest radiography, and echocardiography. Regions of the left ventricle to be treated by TMLR are identified on the basis of ischemic areas noted on the preoperative thallium scan image.

The surgical team does not have to wear special protective gowns during TMLR, but eyes must be shielded with special glasses.

Equipment

A number of different laser technologies were developed while TMLR with the carbon dioxide laser was undergoing US Food and Drug Administration (FDA)-approved trials. The FDA has approved one carbon dioxide system and one holmium:yttrium-aluminum-garnet (YAG) system for this application.[6] The experience described in this article focuses on the carbon dioxide laser. Other laser technologies are not coordinated with electrocardiography (ECG) and therefore may not protect against ventricular arrhythmias. Additionally, the other laser technologies do not produce high energy; therefore, they do not protect against perichannel burns and other forms of tissue destruction around the channels.

Patient preparation

Patients must be prepared and draped in the same manner that they would be for any open heart procedure. Most patients have a Swan-Ganz catheter and an arterial line placed for monitoring. In any reoperative case, external defibrillator pads are applied before the incision is made.

TMLR is performed with the patient under general anesthesia without the use of cardiopulmonary bypass (CPB) or anticoagulation. A double-lumen endotracheal tube is used to allow selective ventilation of the right lung, thus affording better exposure of the heart during the procedure. For monitoring, all patients need ECG, arterial pressure monitoring, Swan-Ganz catheterization, and transesophageal echocardiography (TEE).

Monitoring and follow-up

TMLR is no longer an experimental procedure. Numerous trials have been completed, and long-term follow up data are being collected. Regular follow-up care includes a history, a physical examination, and an evaluation of angina and quality of life. A series of tests, including echocardiography, thallium scanning, and exercise tolerance testing, are regularly performed. Whether TMLR has a significant impact on overall mortality in this patient population remains to be determined.

Previous
Next

Technique

Approach considerations

Transmyocardial laser revascularization (TMLR) is based on the use of a high-powered carbon dioxide or other laser that interjects a strong energy pulse into the left ventricle, vaporizing the ventricular muscle and creating a transmural channel with a 1-mm diameter. The procedure can be used to create channels along the free left ventricular wall but not the septum. These channels are placed 1 cm apart in the ischemic myocardium. TMLR is performed to improve myocardial oxygenation, eliminate or reduce angina, and improve the patient's cardiovascular function.

The carbon dioxide laser is triggered to the electrocardiogram (ECG) to prevent arrhythmias (ventricular tachycardia). Cardiopulmonary bypass (CPB) is not required, and the patient is not heparinized. TMLR is a less invasive procedure, and it is appropriate for minimally invasive surgical incisions. Blood transfusions are rarely required, and recovery appears to be faster and less traumatic.

Clinical trials are investigating the benefits of TMLR compared with continued medical management for patients with angina who are not candidates for either percutaneous coronary angioplasty or coronary artery bypass grafting (CABG). To date, the studies on TMLR show marked decreases in angina and improved functional status for patients with chronic angina.

The precise physiologic mechanism for the efficacy of TMLR is not thoroughly understood. Initially, blood was presumed to flow to the intraventricular chambers through the newly created channels. Today, it is unclear whether this is the exact mechanism by which myocardial blood flow is improved. One theory, albeit an unproven one, is that angiogenesis (growth of new blood vessels) may occur in response to the myocardial tissue injury caused by the laser energy; this may be the process that eventually leads to improved myocardial oxygenation.

Procedure

The heart is approached via an anterolateral thoracotomy through the fifth and sixth intercostal spaces, and the pericardium is opened. Because most of these patients have had prior surgery, all dense adhesions must be carefully excised. In Europe, the thoracoscopic approach has been used in some patients who have not had previous operations.

The energy level for the laser is usually set at 15-60 J, corresponding to a pulse duration of 20-50 msec. The laser probe is placed in contact with the epicardium and fired, thus vaporizing the myocardium in its path and creating a 1-mm wide channel that extends from the surface of the heart to the ventricular cavity. (See the images below)

Laser probe activated into the left ventricular wa Laser probe activated into the left ventricular wall creating a channel.
Laser probe is held on to the surface of the heart Laser probe is held on to the surface of the heart and activated to create channels.
Channels created by transmyocardial laser revascul Channels created by transmyocardial laser revascularization. The bubbles are created and can be visualized on echocardiography.

TMLR can be performed with a carbon dioxide laser or a holmium:yttrium-aluminum-garnet (YAG) laser. Carbon dioxide lasers can deliver up to 1000 W of energy through the myocardium. ECG electrodes are used to synchronize the pulsed carbon dioxide laser to fire with the R wave (corresponding to end diastole), thus minimizing the risk of ventricular arrhythmias. Transesophageal echocardiography (TEE) is used to confirm channel creation when transmural penetration is successful. On the TEE image, steam or bubbles are visualized.

The holmium:YAG laser transmits energy through optical fibers. Because the energy is more readily dissipated, three or four firings are usually required to pass through the entire myocardium. Regardless of the type of laser used, the laser energy vaporizes the myocardial tissue. One channel is created for approximately every square centimeter of ischemic myocardium; thus, a total of 20-40 channels are usually required.

Bleeding from the epicardial surface stops quickly, though local pressure or a suture may occasionally be required to achieve hemostasis. Once the desired number of channels has been created and hemostasis obtained, chest tubes are placed in the pericardial cavity and the incision is closed. An intraoperative TEE study is performed to exclude any injury to the mitral valve apparatus or the septum.

After 25-40 channels are drilled, the pericardium is loosely reapproximated. The chest is then closed in the usual fashion for a small thoracotomy.

Postoperative care

Postoperative care is extremely critical, particularly in regard to the maintenance of the appropriate perfusion pressure in the patient's coronary arterial system.

Patients who undergo TMLR are treated in the same manner as patients undergoing any open heart surgery procedure. After TMLR, all patients are transferred to the intensive care unit (ICU) and weaned off the respirator. Postoperative hemodynamics are monitored, and pressor drips are tapered accordingly. The average stay in the ICU is generally 1 day, after which patients are transferred to a monitored floor bed.

Because of the limited incision, shortened procedure, and nonuse of the CPB machine, most patients recuperate rapidly. The average stay in the hospital is approximately 2-3 days. The hospital stay is extended for patients who develop supraventricular arrhythmias, which must be controlled prior to discharge.

Complications

In more than 1500 patients, intraoperative analysis has documented little morbidity. During the postoperative period, occasional supraventricular tachycardia, pleural effusions, and incisional pain from the thoracotomy have been observed. Because perfusion pressure determines perfusion of the collateral coronary circulation, maintaining adequate perfusion pressure until the patient has recovered completely is important. Hypotension must be avoided, and myocardial support with the use of intra-aortic balloon pumping is sometimes required.

Postoperative myocardial infarctions have been reported and are associated with a mortality of 8-10%. Mortality also appears to be correlated with the left ventricular ejection fraction in all the national studies, with highest early and late mortality in patients with worse left ventricular function.

Previous
 
Contributor Information and Disclosures
Author

Shabir Bhimji, MD, PhD Cardiothoracic and Vascular Surgeon, Saudi Arabia and Middle East Hospitals

Shabir Bhimji, MD, PhD is a member of the following medical societies: American Cancer Society, American College of Chest Physicians, American Lung Association, Texas Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Shreekanth V Karwande, MBBS Chair, Professor, Department of Surgery, Division of Cardiothoracic Surgery, University of Utah School of Medicine and Medical Center

Shreekanth V Karwande, MBBS is a member of the following medical societies: American Association for Thoracic Surgery, American College of Chest Physicians, American College of Surgeons, American Heart Association, Society of Critical Care Medicine, Society of Thoracic Surgeons, Western Thoracic Surgical Association

Disclosure: Nothing to disclose.

Chief Editor

Brett C Sheridan, MD, FACS Associate Professor of Surgery, University of North Carolina at Chapel Hill School of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Jeffrey C Milliken, MD Chief, Division of Cardiothoracic Surgery, University of California at Irvine Medical Center; Clinical Professor, Department of Surgery, University of California, Irvine, School of Medicine

Jeffrey C Milliken, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Thoracic Surgery, American College of Cardiology, American College of Chest Physicians, American College of Surgeons, American Heart Association, American Society for Artificial Internal Organs, California Medical Association, International Society for Heart and Lung Transplantation, Phi Beta Kappa, Society of Thoracic Surgeons, SWOG, Western Surgical Association

Disclosure: Nothing to disclose.

References
  1. van der Sloot JA, Huikeshoven M, Tukkie R, et al. Transmyocardial revascularization using an XeCl excimer laser: results of a randomized trial. Ann Thorac Surg. 2004 Sep. 78(3):875-81; discussion 881-2. [Medline].

  2. Sen PK, Udwadia TE, Kinare SG, Parulkar GB. Transmyocardial acupuncture: A new approach to myocardial revascularization. J Thorac Cardiovasc Surg. 1965 Aug. 50:181-9. [Medline].

  3. Sen PK, Daulatram J, Kinare SG, et al. Further studies in multiple transmyocardial acupuncture as a method of myocardial revascularization. Surgery. 1968 Nov. 64(5):861-70. [Medline].

  4. Mirhoseini M, Cayton MM. Revascularization of the heart by laser. J Microsurg. 1981 Jun. 2(4):253-60. [Medline].

  5. Mirhoseini M, Fisher JC, Cayton M. Myocardial revascularization by laser: a clinical report. Lasers Surg Med. 1983. 3(3):241-5. [Medline].

  6. Kindzelski BA, Zhou Y, Horvath KA. Transmyocardial revascularization devices: technology update. Med Devices (Auckl). 2015. 8:11-9. [Medline].

  7. Gassler N, Wintzer HO, Stubbe HM, et al. Transmyocardial laser revascularization. Histological features in human nonresponder myocardium. Circulation. 1997 Jan 21. 95(2):371-5. [Medline].

  8. Sundt TM, Kwong KF. Clinical experience with the holmium:YAG laser for transmyocardial laser revascularization and myocardial denervation as a mechanism. Semin Thorac Cardiovasc Surg. 1999 Jan. 11(1):19-23. [Medline].

  9. Briones E, Lacalle JR, Marin-Leon I, Rueda JR. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database Syst Rev. 2015 Feb 27. 2:CD003712. [Medline].

  10. Brunsting LA 3rd, Snyder AB, Espinal EA, Srivastava SP. Robotically assisted, completely endoscopic transmyocardial revascularization is feasible. Innovations (Phila). 2014 Sep-Oct. 9 (5):379-82; discussion 382. [Medline].

  11. Frazier OH, Cooley DA, Kadipasaoglu KA, et al. Myocardial revascularization with laser. Preliminary findings. Circulation. 1995 Nov 1. 92(9 Suppl):II58-65. [Medline].

  12. Tavris DR, Brennan JM, Sedrakyan A, et al. Long-term outcomes after transmyocardial revascularization. Ann Thorac Surg. 2012 Nov. 94(5):1500-8. [Medline].

  13. Sansone F, Dato GM, Zingarelli E, et al. Late angiograms ten years after transmyocardial laser revascularization. Coron Artery Dis. 2011 Dec. 22(8):583-4. [Medline].

  14. Babin-Ebell J, Sievers HH, Charitos EI, et al. Transmyocardial laser revascularization combined with intramyocardial endothelial progenitor cell transplantation in patients with intractable ischemic heart disease ineligible for conventional revascularization: preliminary results in a highly selected small patient cohort. Thorac Cardiovasc Surg. 2010 Feb. 58(1):11-6. [Medline].

  15. Abou-Awdi NL, Samuels WL. Transmyocardial laser revascularization. Semin Perioper Nurs. 1995 Jul. 4(3):173-6. [Medline].

  16. Allen KB, Dowling RD, Angell WW, Gangahar DM, Fudge TL, Richenbacher W, et al. Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. Ann Thorac Surg. 2004 Apr. 77(4):1228-34. [Medline].

  17. Allen KB, Dowling RD, Schuch DR, Pfeffer TA, Marra S, Lefrak EA, et al. Adjunctive transmyocardial revascularization: five-year follow-up of a prospective, randomized trial. Ann Thorac Surg. 2004 Aug. 78(2):458-65; discussion 458-65. [Medline].

  18. Cooley DA, Frazier OH, Kadipasaoglu KA, et al. Transmyocardial laser revascularization. Anatomic evidence of long-term channel patency. Tex Heart Inst J. 1994. 21(3):220-4. [Medline].

  19. Cooley DA, Frazier OH, Kadipasaoglu KA, et al. Transmyocardial laser revascularization: clinical experience with twelve-month follow-up. J Thorac Cardiovasc Surg. 1996 Apr. 111(4):791-7; discussion 797-9. [Medline].

  20. Deckelbaum LI. Cardiovascular applications of laser technology. Lasers Surg Med. 1994. 15(4):315-41. [Medline].

  21. Dziuk M, el-Deeb H, Britton KE, et al. [Clinical outcome of patients after transmyocardial laser revascularization alone and combined with coronary artery bypass grafting]. Pol Merkuriusz Lek. 2003 Dec. 15(90):534-6. [Medline].

  22. Fleischer KJ, Goldschmidt-Clermont PJ, Fonger JD, et al. One-month histologic response of transmyocardial laser channels with molecular intervention. Ann Thorac Surg. 1996 Oct. 62(4):1051-8. [Medline].

  23. Galiñanes M, Loubani M, Sensky PR, et al. Efficacy of transmyocardial laser revascularization and thoracic sympathectomy for the treatment of refractory angina. Ann Thorac Surg. 2004 Jul. 78(1):122-8. [Medline].

  24. Horvath KA, Cohn LH, Cooley DA, et al. Transmyocardial laser revascularization: results of a multicenter trial with transmyocardial laser revascularization used as sole therapy for end-stage coronary artery disease. J Thorac Cardiovasc Surg. 1997 Apr. 113(4):645-53; discussion 653-4. [Medline].

  25. Horvath KA, Mannting F, Cummings N, et al. Transmyocardial laser revascularization: operative techniques and clinical results at two years. J Thorac Cardiovasc Surg. 1996 May. 111(5):1047-53. [Medline].

  26. Horvath KA, Smith WJ, Laurence RG, et al. Recovery and viability of an acute myocardial infarct after transmyocardial laser revascularization. J Am Coll Cardiol. 1995 Jan. 25(1):258-63. [Medline].

  27. Kohmoto T, Fisher PE, Gu A, et al. Does blood flow through holmium:YAG transmyocardial laser channels?. Ann Thorac Surg. 1996 Mar. 61(3):861-8. [Medline].

  28. Loubani M, Chin D, Leverment JN, Galinanes M. Mid-term results of combined transmyocardial laser revascularization and coronary artery bypass. Ann Thorac Surg. 2003 Oct. 76(4):1163-6. [Medline].

  29. Mühling OM, Wang Y, Jerosch-Herold M, et al. Improved myocardial function after transmyocardial laser revascularization according to cine magnetic resonance in a porcine model. J Thorac Cardiovasc Surg. 2004 Sep. 128(3):391-5. [Medline].

  30. Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial. Potential Class Improvement From Intramyocardial Channels. Lancet. 2000 Nov 18. 356(9243):1705-10. [Medline].

  31. Peterson ED, Kaul P, Kaczmarek RG, et al. From controlled trials to clinical practice: monitoring transmyocardial revascularization use and outcomes. J Am Coll Cardiol. 2003 Nov 5. 42(9):1611-6. [Medline].

  32. Saririan M, Eisenberg MJ. Myocardial laser revascularization for the treatment of end-stage coronary artery disease. J Am Coll Cardiol. 2003 Jan 15. 41(2):173-83. [Medline].

  33. Satran D, Traverse JH, Barsness GW, et al. Emerging therapies for refractory angina. Minn Med. 2008 Jan. 91(1):36-9. [Medline].

  34. Spiegelstein D, Kim C, Zhang Y, et al. Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival. Am J Physiol Heart Circ Physiol. 2007 Dec. 293(6):H3311-6. [Medline].

  35. Stone GW, St Goar FG, Taussig A, et al. First experience with hybrid percutaneous transmyocardial laser revascularization and angioplasty in patients with lesions at high risk for restenosis: Results of a phase I feasibility study. Am Heart J. 2001 Oct. 142(4):679-83. [Medline].

  36. Wehberg KE, Julian JS, Todd JC 3rd, Ogburn N, Klopp E, Buchness M. Improved patient outcomes when transmyocardial revascularization is used as adjunctive revascularization. Heart Surg Forum. 2003. 6(5):328-30. [Medline].

  37. White M, Hershey JE. Multiple transmyocardial puncture revascularization in refractory ventricular fibrillation due to myocardial ischemia. Ann Thorac Surg. 1968 Dec. 6(6):557-63. [Medline].

  38. Whitlow PL, DeMaio SJ, Perin EC, et al. One-year results of percutaneous myocardial revascularization for refractory angina pectoris. Am J Cardiol. 2003 Jun 1. 91(11):1342-6. [Medline].

  39. Whittaker P, Rakusan K, Kloner RA. Transmural channels can protect ischemic tissue. Assessment of long- term myocardial response to laser- and needle-made channels. Circulation. 1996 Jan 1. 93(1):143-52. [Medline].

 
Previous
Next
 
Laser probe activated into the left ventricular wall creating a channel.
Laser probe is held on to the surface of the heart and activated to create channels.
Channels created by transmyocardial laser revascularization. The bubbles are created and can be visualized on echocardiography.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.